UM researchers home in on prostate cancer biomarkers; Courtagen receives $8 million influx;

> While PSA testing is under debate for its accuracy, researchers at the University of Michigan have found two potential biomarkers for prostate cancer detection--TMPRSS2:ERG and PCA3 DNA. The researchers say the biomarkers are found in high quantities in 95% of prostate cancers, and can be monitored via a urine test. Release

> Rather than focusing on lifestyle indicators or specific inflammation as signs of heart disease, UC Davis researchers stressed the importance of systemic inflammation and highlighted three biomarkers--fibrinogen, C-reactive protein and serum amyloid-A--that are more stable warnings regardless of age, gender or race. Report

> Tethys Bioscience has received approval from the New York State Department of Health to use its PreDx Diabetes Risk Score test on state residents' blood samples. The test identifies individuals at high risk of developing type 2 diabetes in the next 5 years via multiple biomarkers. Tethys release

> Courtagen has gained the confidence of 67 financial investors, raising $8 million in equity investments. The company focuses on protein biomarker detection. Item

And Finally... Other researchers at the University of Michigan have found "computational biomarkers" that better predict mortality rates in acute coronary syndrome patients. The indicators can be determined using data commonly collected during hospital admissions. Story

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.